Sarepta Therapeutics’ (SRPT) “Sell (D-)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Tuesday morning,Weiss Ratings reports.

A number of other analysts have also recently weighed in on the stock. Wolfe Research initiated coverage on shares of Sarepta Therapeutics in a report on Tuesday, June 17th. They issued a “peer perform” rating on the stock. BMO Capital Markets raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a report on Monday, September 22nd. Leerink Partners increased their price objective on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a report on Tuesday, September 9th. Barclays raised shares of Sarepta Therapeutics from an “underweight” rating to an “equal weight” rating and set a $22.00 price objective on the stock in a report on Tuesday, July 29th. Finally, Robert W. Baird raised their target price on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $34.42.

Sarepta Therapeutics Trading Down 2.4%

Sarepta Therapeutics stock opened at $21.43 on Tuesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. Sarepta Therapeutics has a 1 year low of $10.41 and a 1 year high of $138.81. The firm’s 50-day moving average is $19.30 and its 200-day moving average is $30.04. The company has a market cap of $2.09 billion, a P/E ratio of -24.63 and a beta of 0.51.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million for the quarter, compared to analysts’ expectations of $530.66 million. During the same quarter last year, the company earned $0.07 EPS. The company’s revenue for the quarter was up 68.4% compared to the same quarter last year. On average, equities analysts expect that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in SRPT. Federated Hermes Inc. grew its stake in shares of Sarepta Therapeutics by 347.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock worth $22,370,000 after purchasing an additional 1,016,069 shares during the last quarter. Norges Bank acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $15,619,000. Y Intercept Hong Kong Ltd grew its stake in shares of Sarepta Therapeutics by 1,736.5% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company’s stock worth $14,880,000 after purchasing an additional 822,799 shares during the last quarter. Aberdeen Group plc grew its stake in shares of Sarepta Therapeutics by 91.1% in the 2nd quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock worth $21,500,000 after purchasing an additional 592,125 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Sarepta Therapeutics by 27.9% in the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock worth $168,907,000 after purchasing an additional 577,848 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.